Validation of Clinical Treatment Score post-5 years (CTS5) risk stratification in premenopausal breast cancer patients and Ki-67 labelling index

Clinical validity of CTS5 for estimating risk of late recurrence in unselected, non-trial patients with early ER+ breast cancer.

(2019) Juliet Richman et al.   JOURNAL OF CLINICAL ONCOLOGY

Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor–Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5

(2018) Mitch Dowsett et al.   JOURNAL OF CLINICAL ONCOLOGY

Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update

(2018) Antonio C. Wolff et al.   JOURNAL OF CLINICAL ONCOLOGY

Beyond 5 years: enduring risk of recurrence in oestrogen receptor-positive breast cancer

(2018) Juliet Richman et al.   Nature Reviews Clinical Oncology

Optimal Ki67 cut-off for luminal breast cancer prognostic evaluation: a large case series study with a long-term follow-up

(2016) Sara Bustreo et al.   BREAST CANCER RESEARCH AND TREATMENT

Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years

(2016) Paul E. Goss et al.   NEW ENGLAND JOURNAL OF MEDICINE

Differences in Incidence, Mortality and Survival of Breast Cancer by Regions and Countries in Asia and Contributing Factors

(2015) Yeonju Kim et al.   Asian Pacific Journal of Cancer Prevention

Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer

(2015) Hiroko Yamashita et al.   Breast Cancer

Long-Term Prognostic Performance of Ki67 Rate in Early Stage, pT1-pT2, pN0, Invasive Breast Carcinoma

(2013) Fabien Reyal et al.   PLoS One

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

(2012) Christina Davies et al.   LANCET

Biologic markers determine both the risk and the timing of recurrence in breast cancer

(2011) Laura J. Esserman et al.   BREAST CANCER RESEARCH AND TREATMENT

Heterogeneity in breast cancer

(2011) Kornelia Polyak   JOURNAL OF CLINICAL INVESTIGATION

Breast Cancer Adjuvant Therapy: Time to Consider Its Time-Dependent Effects

(2011) Ismail Jatoi et al.   JOURNAL OF CLINICAL ONCOLOGY

Unique features of breast cancer in Asian women—Breast cancer in Taiwan as an example

(2010) Chiun-Sheng Huang et al.   JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial

(2010) Jack Cuzick et al.   LANCET ONCOLOGY